Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure

IMPORTANCE: Emerging evidence has consistently demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) hospitalization and cardiovascular (CV) death among patients with HF. However, it remains unclear how long a patient needs to live to potentially b...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, KangYu, Nie, Zhiqiang, Shi, Rui, Yu, Dahai, Wang, Qi, Shao, Fang, Wu, Guohong, Wu, Zhenqiang, Chen, Tao, Li, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450563/
https://www.ncbi.nlm.nih.gov/pubmed/37615988
http://dx.doi.org/10.1001/jamanetworkopen.2023.30754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10450563/
https://www.ncbi.nlm.nih.gov/pubmed/37615988
http://dx.doi.org/10.1001/jamanetworkopen.2023.30754

Ejemplares similares